Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy

被引:12
|
作者
Eitel, Tamara [1 ]
Zeiner, Kim Nikola [1 ]
Assmus, Katharina [1 ]
Ackermann, Hanns [2 ]
Zoeller, Nadja [1 ]
Meissner, Markus [1 ]
Kaufmann, Roland [1 ]
Kippenberger, Stefan [1 ]
Valesky, Eva Maria [1 ]
机构
[1] Goethe Univ Frankfurt, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Dept Biostat & Math Models, Frankfurt, Germany
来源
WORLD ALLERGY ORGANIZATION JOURNAL | 2021年 / 14卷 / 05期
关键词
Hymenoptera venom allergy; Immunotherapy; Sting challenge; Quality of life; DEBILITATING BELIEFS; EMOTIONAL DISTRESS; HOSPITAL ANXIETY; DEPRESSION SCALE; INSECT; EPIDEMIOLOGY; VERSION; HADS;
D O I
10.1016/j.waojou.2021.100536
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients' quality of life (QoL). Besides carrying emergency medication, venom specific immunotherapy (VIT) exists as a causal treatment of allergy. Objective: This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC). Methods: Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36).To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n =45), (B) VIT before carrying out SC (n = 73), and (C) therapy-na & iuml;ve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed. Results: A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients' age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men. Conclusion: Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients' QoL.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Specific immunotherapy for Hymenoptera venom anaphylaxis: current issues
    Przybilla, Bernhard
    Rueff, Franziska
    Fuchs, Thomas
    ALLERGO JOURNAL, 2008, 17 (06) : 461 - 465
  • [42] Immunotherapy for Hymenoptera venom allergy compared with real-life stings: Are we doing our best?
    Pecoraro, Luca
    Giovannini, Mattia
    Mori, Francesca
    Saretta, Francesca
    Barni, Simona
    Castagnoli, Riccardo
    Arasi, Stefania
    Mastrorilli, Carla
    Liotti, Lucia
    Caminiti, Lucia
    Novembre, Elio
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (02) : 209 - 211
  • [43] Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy
    Siegmund, R
    Vogelsang, H
    Machnik, A
    Herrmann, D
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (06) : 1190 - 1195
  • [44] THE ADHESION MOLECULE ICAM-1 IS OVEREXPRESSED IN PATIENTS WITH HYMENOPTERA VENOM ALLERGY AND DECREASES AFTER ULTRARUSH VENOM IMMUNOTHERAPY
    Patella, V.
    Incorvaia, C.
    Ricciardi, L.
    Florio, G.
    Saija, A.
    Frati, F.
    Gangemi, S.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2011, 25 (03) : 465 - 468
  • [45] Hymenoptera venom allergy and immunotherapy - what a General Practitioner should know
    Mazurkiewicz, Zuzanna
    Hak, Zofia Maria
    Pilszyk, Zuzanna Maria
    Pilszyk, Aleksandra ElZbieta
    Gomulka, Krzysztof
    FAMILY MEDICINE AND PRIMARY CARE REVIEW, 2021, 23 (01) : 93 - 97
  • [46] Hymenoptera sting in the head and neck region is not a risk factor for grade IV systemic reactions in patients with venom allergy
    Cichocka-Jarosz, Ewa
    Nittner-Marszalska, Marita
    Mol, Nina
    Stobiecki, Marcin
    Brzyski, Piotr
    Chruszczewska, Ewa
    Jedynak-Wasowicz, Urszula
    Tomasik, Tomasz
    Czarnobilska, Ewa
    Lis, Grzegorz
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2019, 129 (03): : 160 - 166
  • [47] Fear of stinging insects in relation to state anxiety and trait anxiety in a group of patients with hymenoptera venom allergy undergoing immunotherapy
    Wozniewicz, Agnieszka
    Szynkiewicz, Ewa
    Palgan, Krzysztof
    Graczyk, Malgorzata
    Dowbor-Dzwonka, Aneta
    Bartuzi, Zbigniew
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2019, 36 (04): : 472 - 477
  • [48] Evaluation of a semi-quantitative westernblot method for hymenoptera venom allergy before, during and after specific immunotherapy
    Freising, C
    Jappe, U
    ALLERGOLOGIE, 2006, 29 (02) : 46 - 56
  • [49] Hymenoptera sting challenge of 348 patients: Relation to subsequent field stings
    vanHalteren, HK
    vanderLinden, PWG
    Burgers, SA
    Bartelink, AKM
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (05) : 1058 - 1063
  • [50] Specific Immunotherapy in Hymenoptera Venom Allergy and Concomitant Malignancy: A Retrospective Follow-up Focusing on Effectiveness and Safety
    Aeberhard, J.
    Haeberli, G.
    Mueller, U. R.
    Helbling, A.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2017, 27 (06) : 370 - 377